Oncology and X-Ray products company,
Varian Medical Systems
(
VAR
) recently revealed the issuance of its 2012 Corporate Social
Responsibility report. This document provides details of the
company's goals and accomplishments in preserving resources,
providing support and helping to protect lives. The Varian
Sustainability Report 2012 is an integral part of the company's
overall effort to enhance performance in the sphere of
sustainability.
Varian remains committed to providing annual updates of its
progress in meeting sustainability objectives. It believes that it
has a duty to meet official goals in an eco friendly and socially
responsible manner.
Varian is a leading manufacturer of integrated radiotherapy systems
for cancer treatment, and a premier supplier of X-ray tubes for
diagnostic imaging applications. The company operates in a
technology-driven environment where success depends on the use of
new technology, product development and upgrades. In the radiation
oncology market, Varian competes with
Accuray
(
ARAY
).
The company is poised to increase its market share in radiation
oncology. It currently enjoys a healthy demand for its coveted
TrueBeam technology, which has meaningfully contributed to its net
order oncology growth. Varian's TrueBeam was designed to treat
tumors with beams of high speed and precision. It incorporates
several technological innovations such as patient positioning and
managing his/her motion. It can dispense dosage roughly four times
faster than that possible with earlier equipment.
Moreover, Varian enjoys a strong balance sheet marked by low debt
and moderate cash. The company from time to time uses a part of its
healthy cash flow for share repurchases.
However, Varian competes with larger players in a
technology-intensive industry. Further, uncertainties stemming from
health care reform and a still weak hospital capital spending
environment across many developed countries, especially in Europe,
are significant challenges.
We are currently 'Neutral' on Varian. The stock retains a Zacks #3
Rank, which translates into a short-term Hold rating.
ACCURAY INC (ARAY): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research